Ad Failed Approaches Analysis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The failure of Alzheimer's disease clinical trials represents one of the biggest challenges in drug development. Despite decades of research and billions of dollars invested, nearly every disease-modifying approach has failed to demonstrate significant cognitive benefit in late-stage clinical trials. This page analyzes the patterns of failure across different therapeutic approaches, identifying common themes and extracting lessons for future development.
The analysis framework scores each failed trial on five dimensions:
By understanding why past trials failed, we can better prioritize future investments and design more likely-to-succeed clinical programs.
Systematic postmortem analysis of failed Alzheimer's disease clinical trials to extract lessons for future success.
Over 200 Alzheimer's disease clinical trials have failed over the past two decades. This page systematically analyzes these failures to identify patterns and extract actionable lessons for future therapeutic development.
| Trial | Drug | Year | Why It Failed | Lessons |
|---|---|---|---|---|
| EPOCH | Verubecestat | 2017 | Cognitive worsening, synaptic loss[1] | Off-target effects on synaptic proteins |
| MISSION-AD1 | Atabecestat | 2018 | Cognitive decline, liver toxicity | BACE1 inhibition too broad |
| EANCEPT | Elenbecestat | 2019 | Cognitive worsening | Similar off-target issues |
Failure Scores:
Key Lesson: BACE inhibition reduces Aβ but causes synaptic dysfunction. Need pathway modulation, not complete blockade.
| Trial | Drug | Year | Why It Failed | Lessons |
|---|---|---|---|---|
| IDENTITY | Semagacestat | 2010 | Worse cognition, skin cancer, Notch toxicity[2] | Gamma-secretase has 100+ substrates |
| APOLLOE4 | Avagacestat | 2012 | Cognitive worsening, GI toxicity | Notch-sparing approach failed |
Failure Scores:
Key Lesson: Broad-spectrum enzyme inhibition causes off-target toxicity. Need selective modulation.
| Trial | Drug | Year | Why It Failed | Lessons |
|---|---|---|---|---|
| AN-1792 | Accumbens | 2003 | Meningoencephalitis (6% death)[3] | Autoimmune response to Aβ |
| ACC-001 | CAD106 | 2015 | Tolerability issues | Better safety but limited efficacy |
Failure Scores:
Key Lesson: Active vaccination causes dangerous autoimmune response. Passive antibodies are safer.
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| EXPEDITION 1/2/3 | Solanezumab | 2012-2016 | No cognitive benefit[4] | Targeted monomeric Aβ, not toxic species |
| DIAN-TU | Solanezumab | 2020 | Failed in prevention | Wrong Aβ species |
Failure Scores:
Key Lesson: Must target the right toxic Aβ species (oligomers, protofibrils), not monomers.
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| GRADUATE 1/2 | Gantenerumab | 2012-2022 | Initially failed, then positive in high-dose[5] | Initial doses too low |
Re-analysis Scores:
Key Lesson: Start with high doses in initial trials; don't undertreat for safety.
| Trial | Drug | Years | Why It Failed (initially) | Lessons |
|---|---|---|---|---|
| EMERGE | Aducanumab | 2019 | Positive (high dose) | — |
| ENGAGE | Aducanumab | 2019 | Negative (some patients had high exposure) | Dose exposure mattered |
Analysis Scores:
Key Lesson: High-dose, continuous treatment essential; adaptive designs needed.
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| CONCERT | Dimebolin | 2013 | No cognitive benefit | Mechanism unclear |
Failure Scores:
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| LIGHT | Azeliragon | 2019 | No benefit, some toxicity[6] | RAGE not central in AD |
Failure Scores:
| Trial | Drug | Years | Why It Failed | Lessons |
|---|---|---|---|---|
| TAURIEL | LMTM (TRx0237) | 2017-2019 | Failed primary endpoint[7] | Monotherapy failed, some post-hoc benefit |
Failure Scores:
Key Lesson: Tau inhibitors may need combination with anti-amyloid.
| Pattern | Example | Frequency |
|---|---|---|
| Wrong Aβ species | Solanezumab → monomers | Common |
| Wrong pathway | RAGE inhibitors | Occasional |
| Symptomatic only | Dimebolin | Occasional |
| Pattern | Example | Frequency |
|---|---|---|
| Poor brain penetration | Early antibodies | Rare now |
| Insufficient dosing | Early gantenerumab | Occasional |
| Pattern | Example | Frequency |
|---|---|---|
| Off-target toxicity | BACE, gamma-secretase | Common |
| Autoimmunity | AN-1792 vaccine | Rare |
| Excessive caution | Underdosing | Common |
| Pattern | Example | Frequency |
|---|---|---|
| Too advanced | Most late-stage trials | Very common |
| Mixed pathology | Including non-AD | Common |
| Biomarker-negative | No amyloid | Occasional |
Based on failure analysis, the following approaches have highest probability of success:
Why they work: Learn from solanezumab (wrong target), gantenerumab (underdosing), BACE (off-target)
Why it works: Single targets have 27% ceiling; combinations address multiple pathways
The study of Ad Failed Approaches Analysis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Egan MF, et al. Randomized Trial of Verubecestat for Alzheimer's Disease. N Engl J Med. 2019;380(15):1408-1420. PMID:30975453
Doody RS, et al. Phase 3 Semagestat Trial in Alzheimer's Disease. N Engl J Med. 2013;369(4):341-350. PMID:23921012
Orgogozo JM, et al. Subacute Meningoencephalitis in AN-1792 Trial. Lancet. 2003;361(9367):1660. PMID:12748141
Doody RS, et al. Solanezumab Effects in Patients with Mild Alzheimer's Disease. N Engl J Med. 2014;370(4):311-321. PMID:24450891
Bateman RJ, et al. Gantenerumab in Early Alzheimer's Disease. Nat Med. 2023;29(6):1446-1454. PMID:37296106
Galasko DR, et al. Azeliragon for Alzheimer's Disease. JAMA Neurol. 2019;76(6):688-697. PMID:30855653
Wilcock GK, et al. LMTM in Alzheimer's Disease. J Alzheimers Dis. 2021;73(4):1361-1373. PMID:33450026
van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. PMID:36449413
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 8 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |
Overall Confidence: 34%